Eisai Co. Ltd. has announced a strategic collaboration with Merck, known as MSD outside the United States and Canada, to co-develop and co-commercialize the cancer treatment lenvatinib. This partnership will see the two companies working together on both monotherapy applications and combinations with Merck's anti-PD-1 therapy, pembrolizumab. The collaboration includes a focus on the LEAP clinical program, which explores the combination of lenvatinib and pembrolizumab in treating hepatocellular carcinoma and esophageal cancer across various clinical trials. This initiative highlights Eisai and Merck's commitment to advancing oncology treatment options and improving patient outcomes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。